Encouraging SRC Findings on Ph I/II Skin Cancer Trial
Filed with ASX · · 4 pages · English
Earlier from Invion
- Dosing of 1st Six Patients in Phase I/II Skin Cancer Trial
- Appendix 4C and Quarterly Activities Report - March 2025
- Share Purchase Agreement Termination and Tranche Repayment
- Completion Of Placement to Accelerate Clinical Programs
- Oesophageal Cancer Collaboration and Funding Agreement
Later from Invion
- Loyalty Option Entitlement Offer
- EQR Progresses Regional Tungsten Hub Strategy
- Underwritten Loyalty Option Entitlement Offer Prospectus
- Security Class Suspension from Quotation
- Security Class Reinstatement to Quotation
Follow Invion into a list and get an email when it puts out news.
Follow Invion